x
ServiziMenu principaleHome
You are here: Home > Events > Future Events > Where medical and radiation oncology meet: integrating state of the art strategies
Print

Where medical and radiation oncology meet: integrating state of the art strategies

27.02.2019  -  01.03.2019

Tel Aviv, Israel

ADVANCED COURSES & SEMINARS

Radiation oncology

Description

Chairs: J. Bernier, CH - F. Calvo, ES - D. Vorobiof, ZA/IL
Host Chair: A. Kuten, IL
Local Organizing and Scientific Committee: R. Pfeffer, IL - I. Ben Aharon, IL - S. Paluch-Shimon, IL - J. Bar, IL - W. Mermershtain, IL - F. Atrash, IL
AROME Co-Organizers: J. Gligorov, FR - Y. Belkacemi, FR - M. Ozsahin, CH


FOREWORD

This 3-day ESO course is dedicated to the latest developments in the local and systemic personalized management of breast cancer, gastro-intestinal cancer, lung cancer and cancer of the head & neck. Lectures will be given by a faculty consisting of leading European and Israeli cancer experts who will focus on innovative treatment strategies and combination of systemic therapy and precision radiotherapy. The course is open to all cancer professionals - medical and radiation oncologists, surgical oncologists, gastroenterologists, pulmonologists and cancer biologists. Oncology nurses, RT physicists and technologists as well as medical students are welcome.

LEARNING OBJECTIVES
• Update the knowledge in the local and systemic personalized management of breast cancer, gastro-intestinal cancer, lung cancer and cancer of the head & neck
• Become aware of innovative strategies in combined modality therapy of the above malignancies
• Learn how to incorporate the innovative strategies in drug therapy and precision radiotherapy in daily practice

Held in collaboration with        
       
With the support of        
       

Faculty

FACULTY (as of January 2019)
F. Atrash, Augusta Victoria Hospital, Dept. of Oncology, Jerusalem, IL
J. Bar, Sheba Medical Center, Cancer Institute, Oncology Dpt., Ramat Gan, IL
E. Bar-Meir, Padeh Poria Medical Center, Plastic Surgery Dpt., Tiberias, IL
Y. Belkacemi, Hôpital Henri Mondor, Radiation Oncology and Breast Center Dpt., Creteil, FR
A. Ben Nun, Sheba Medical Center, Cancer Institute, Thoracic Surgery Dpt., Ramat Gan, IL
R. Ben Yosef, Rambam Health Care Campus, Division of Oncology, Radiotherapy Unit, Haifa, IL
I. Ben-Aharon, Rambam Health Care Campus, Division of Oncology, Haifa, IL
N. Ben-Baruch, Kaplan Medical Center, Dept. Of Oncology, Rehovot, IL
D. Benchimol, Rabin Medical Center, Beilinson Campus, Dept. of Surgery, Petach Tikva, IL
R. Berger, Sheba Medical Center, Cancer Institute, Oncology Dpt., Ramat Gan, IL
J. Bernier, Genolier Cancer Center, Dept. of Radio-Oncology, Genolier, CH
S. Billan, Rambam Health Care Campus, Division of Oncology, Radiotherapy Unit, Haifa, IL
B. Brenner, Rabin Medical Center, Davidoff Cancer Center, Petach Tikva, IL
F. Calvo Manuel, Clinica Universidad de Navarra, Dept. of Radiation Oncology, Pamplona, Navarra, ES
R. Catane, Sheba Medical Center, Cancer Institute, Oncology Dpt., Ramat Gan, IL
R. Dziadziuszko, Medical University of Gdansk, Oncology and Radiotherapy Dpt., Gdansk, PL
P. Franco, Università di Torino, Scuola di Medicina, Dept. of Oncology, Radiation Oncology, Torino, IT
O. Gentilini, St. Raffaele Hospital, Dept. of Breast Surgery, Milan, IT
R. Geva, Tel Aviv Sourasky Medical Centre, Dept. of Oncology, Tel Aviv, IL
E. Gez, Ziv Medical Center, Oncology Dept., Zefat, IL
J. Gligorov, APHP Tenon, IUC-UPMC, Sorbonne University, Dept. of Medical Oncology, Paris, FR
M. Gottfried, Meir Medical Center, Oncology Dpt., Kfar Saba, IL
K. Haustermans, Uz Leuven, Radiation Oncology Department, Leuven, BE
M. Inbar, Assuta Medical Centres, Oncology Dpt., Tel Aviv, IL
B. Kaufman, Sheba Medical Center, Cancer Institute, Oncology Dpt., Ramat Gan, IL
D. Keizman, Meir Medical Center, Genitourinary Oncology Unit, Kfar-Saba, IL
A. Kuten, Italian Hospital of Haifa, Dept.of Oncology, Haifa, IL
P. Lara, San Roque University Hospital, Fernando Pessoa Canarias University, Oncology Dpt., Las Palmas, ES
Y. Lawrence, Sheba Medical Center, Cancer Institute, Radiotherapy Dpt., Ramat Gan, IL
R. Leibowitz, Sheba Medical Center, Cancer Institute, Oncology Dpt., Ramat Gan, IL
E. Levy Lahad, Shaare Zedek Medical Center , Medical Genetics Institute, Jerusalem, IL
S. Man, Soroka University Medical Center, Dept. of Oncology, Beer Sheva, IL
E. M. Marom, Sheba Medical Center, Cancer Institute, Diagnostic Radiology Dpt., Ramat Gan, IL
W. Mermershtain, Israel Society of Oncology and Radiotherapy, Beer Sheva, IL
E. Ozsahin, Centre Hospitalier Universitaire Vaudois (CHUV), Dept. of Radiation Oncology, Lausanne, CH
S. Paluch-Shimon, Shaare Zedek Medical Center, Breast Cancer Unit, Jerusalem, IL
F. Peccatori, European Institute of Oncology, Dept. of Fertility and Procreation in Oncology, Milano, IT
A. Peer, Rambam Health Care Campus, Division of Oncology, Haifa, IL
N. Peled, Soroka Medical Center, Dept. of Oncology, Beer Sheva, IL
R. Pfeffer, Assuta Medical Center, Dept. of Oncology, Radiotherapy Unit, Tel Aviv, IL
P. Poortmans, Curie Institute, Dept. of Radiation Oncology, Paris, FR
G. Rennert, Carmel Medical Ctr., Department of Community Medicine and Epidemiology, Haifa, IL
E. Rosenbaum, Rabin Medical Center, Davidoff Cancer Center, Petach Tikva, IL
E. Smyth, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
E. Shacham Shmueli, Sheba Medical Center, Dept. of Oncology, Ramat Gan, IL
Y. Shiloh, Tel Aviv University, Human Molecular Genetics and Biochemistry Dpt, Tel Aviv, IL
K. Shulman, Hillel Yaffe Medical Center, Oncology Dpt., Hadera, IL
Z. Symon, Sheba Medical Center, Cancer Institute, Radiotherapy Dpt., Ramat Gan, IL
P. Van Houtte, Institute Jules Bordet, Dept. of Radiation Oncology, Bruxelles, BE
D. Vorobiof, Sandton Oncology Centre, Oncology Dpt., Johannesburg, SA
M. Wygoda, Sharett Institute of Oncology, Radiotherapy Unit, Hadassah University Hospital, Jerusalem, IL
M. Wollner, Rambam Health Care Campus, Division of Oncology, Haifa, IL
R. Yerushalmi, Rabin Medical Center, Davidoff Cancer Center, Petach Tikva, IL
A. Zer, Rabin Medical Centre, Davidoff Cancer Center, Petach Tikva, IL
M. Ziv, Israel Cancer Association, Director Office, Givatayim, IL

General information

ORGANISING SECRETARIAT
European School of Oncology
Via Turati 29
20121 Milan
Italy
Francesca Marangoni
E-mail: fmarangoni@eso.net
Phone: +39 02 85464525

LOCAL ORGANISER AND REGISTRATION
I.M. Knasim Ltd
4 Ariel Sharon St., Givatayim
Ayelet Levy
knasim@imknasim.co.il
Tel: +972-3-6081520
Fax:+972-3-6081522

VENUE
Kfar Maccabiah Hotel
Perets Bernstein 7 st. P.O. Box 919
Ramat-Gan
5224771 Israel
www.kmc-hotel.co.il

CME ACCREDITATION
Participants will be entitled to receive a certificate of attendance at the close of the course by completing the online evaluation questionnaire.
The event has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS). The evaluation of the event has been performed by the Accreditation Council of Oncology in Europe (ACOE) that acknowledged the quality of the scientific programme and its educational value. The event is designated for a maximum of 13 European CME credits (ECMEC). Through an agreement between UEMS and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™.

OFFICIAL LANGUAGE
The course will be held in English and no translation will be provided.

BADGE
The name badge is the only official evidence of registration and should be worn at all times during the course.

INSURANCE
The organisers bear no responsibility for untoward events in relation to the participation in the course. Participants are advised to take out their own personal and travel insurance.

Registration

REGISTRATION
The registration fee includes participation in all sessions, coffee breaks and lunches as described in the programme and access to the event dedicated website.

REGISTRATION FEES: (Israeli shekels)

 

Pre-registration
(by 17 February)

On site
(from 18 February)

Regular fee

IS 200

IS 300

Discounted fee*

IS 120

IS 180

* Resident doctors in training, physicists, radiotherapy technologists, nurses, cancer biologists,
dosimetrists
* Discounted fee for participants from lower- and upper-middle-income economies as defined by The
World Bank

HOW TO APPLY
Please fill in the form (downloadable HERE) in BLOCK CAPITALS and send by by 17 February to:
I.M. Knasim Ltd | Attn. Mrs. Ayelet Levy | 4 Ariel Sharon St., Givatayim | E-mail: knasim@imknasim.co.il
Tel: +972-3-6081520 | Fax:+972-3-6081522

Accommodation

HOTEL ACCOMMODATION
Accommodation at the course venue (Kfar Maccabiah Hotel) may be reserved through I.M. Knasim. For further information, please contact knasim@imknasim.co.il.

Programme

27 February

8:00 Welcome and opening address
A. Kuten, IL - J. Bernier, CH - F. Calvo, ES - M. Ziv, IL - M. Mermershtain, IL
BREAST CANCER: THE IMPACT OF MOLECULAR SUBTYPING ON LOCO-REGIONAL AND SYSTEMIC TREATMENT OF BREAST CANCER
Chairs: N. Ben-Baruch, IL - M. Inbar, IL
8:30 Impact on surgical management
O. Gentilini, IT
8:50 Impact on systemic therapy
J. Gligorov, FR
9:10 Impact on loco-regional therapy and radiotherapy in the setting of breast reconstruction
Y. Belkacemi, FR
9:30 Impact on multimodality care in the neo-adjuvant setting
R. Yerushalmi, IL
9:50 Regional lymph node treatment in breast cancer: when, which and how
P. Poortmans, FR
10:15 Coffee break
BREAST CANCER- SPECIAL POPULATIONS & UNIQUE ASPECTS OF CARE
Chairs: B. Kaufman, IL - E. Bar-Meir, IL
10:45 Genetic testing for hereditary cancer - state of the art
E. Levy-Lahad, IL
11:00 Reproductive considerations in the BRCA+ breast cancer patient
F. Peccatori, IT
11:15 Management of the BRCA+ patient with breast cancer
S. Paluch-Shimon, IL
11:30 Unique surgical considerations in young patients and BRCA+ patients
O. Gentilini, IT
11:45 Tumour board - case discussions
12:30 Lunch
LUNG CANCER - INTEGRATIVE APPROACHES
Chairs: R. Pfeffer, IL - N. Peled, IL
13:30 Interpretation pitfalls in lung cancer follow up
E.M. Marom, IL
13:50 Early stage NSCLC - SBRT vs. surgery
P. van Houtte, BE
14:10 Immunotherapy in early stage NSCLC
J. Bar, IL
14:30 Coffee break
LUNG CANCER - LOCALLY ADVANCED
Chairs: A. Zer, IL - M. Wollner, IL
15:00 Stage III NSCLC - radiotherapy aspects
P. van Houtte, BE
15:20 Stage III NSCLC - systemic treatments
R. Dziadziuszko, PL
15:40 Stage III NSCLC - surgical approach
A. Ben-Nun, IL
16:00 Lung cancer panel - cases
Moderator: M. Gottfried, IL + all of the above speakers

28 February

CANCER OF THE HEAD AND NECK
Chairs: J. Bernier, CH - S. Billan, IL
8:30 Integration of RT and systemic therapy (chemo-, targeted-, immune-therapy) in cancer of the Head and Neck
M. Ozsahin, CH
GENITO-URINARY CANCER (PART I)
Chairs: E. Gez, IL - E. Rosenbaum, IL
9:00 Localised bladder cancer
M. Wygoda, IL
9:20 Systemic therapy of kidney and bladder cancer
D. Keizman, IL
9:40 Non-metastatic prostate cancer-selection of therapy
Z. Symon, IL
10:10 Coffee break
GENITO-URINARY CANCER (PART II)
Chairs: R. Berger, IL - E. Gez, IL
10:40 Metastatic Prostate cancer - systemic therapy
A. Peer, IL
11:00 Metastatic Prostate cancer - is there a role for loco-regional therapy?
R. Ben Yosef, IL
11:20 Case presentation and panel discussion
Moderator: R. Leibowitz, IL + all of the above speakers
12:15 Lunch
GASTRO INTESTINAL CANCER: LOCALLY ADVANCED DISEASE
Chairs: D. Vorobiof, ZA/IL - B. Brenner, IL
13:15 Neoadjuvant chemo-RT vs perioperative chemotherapy in GEJ cancer
E. Smyth, UK
13:45 Pancreatic Cancer: the role of loco-regional therapy
Y. Lawrence, IL
14:15 Rectal Cancer: New venues of treatment in rectal cancer. Can we reduce the need for radiotherapy or radical surgery?
K. Haustermans, BE
14:45 Coffee break
GASTRO INTESTINAL CANCER: METASTATIC DISEASE
Chairs: K. Shulman, IL - S. Man, IL
15:15 The role of cytoreductive surgery and HIPEC in metastatic CRC
D. Benchimol, IL
15:45 The role of metastasis targeted therapy in GI tumors
R. Geva, IL
16:15 Case presentation and panel discussion
Moderator: E. Shacham Shmueli and all of the above speakers

1 March

CAN WE CURE METASTATIC DISEASE? (OLIGOMETS, IMMUNE SYSTEM, GENOMICS & PROTEOMICS)
Chairs: F. Atrash, IL - R. Catane, IL
8:30 Oligometastases - do they exist and can we change the treatment paradigm
R. Pfeffer, IL
8:55 Radiation effects on the immune system
J. Bar, IL
9:15 Genomic considerations in the selection of treatment
G. Rennert, IL
9:40 The cancer genome landscape and omics - a deeper insight into cancer biology
I. Ben-Aharon, IL
10:00 Maintenance of genome stability: at the crossroads between cancer causation - and treatment
Y. Shiloh, IL
10:30 Coffee break
CANCER EDUCATION
11:00 European School of Oncology - opportunities for on-line cancer education
P.F. Franco, IT
11:20 Oncology and radiotherapy training in the 21st century: where are we going
P. Lara, ES
11:50 What is needed to improve cancer education in medical schools
R. Pfeffer, IL
12:10 Minimal requirements for cancer care in the Mediterranean Area: AROME consensus
J. Gligorov, FR
12:30 Closing ceremony
R. Pfeffer, IL
12:45 Lunch

 

Follow us